Logo
Title
Regulatory Rapporteur February 2022
Summary
Expedited pathways: How expedited pathways benefit patients and the industry Plus: • Article: Selection and justification of regulatory starting materials • Interview: Building best regulatory practices in Brazil • Meeting Report: The EMA’s Veterinary Big Data Stakeholder Forum (Part 2)
DocumentAccess
Regulatory Rapporteur February 2022MEMBERS
Conditional oncology drug approvals: A sponsor's perspective on the evolving landscape of FDA accelerated approvalsMEMBERS
Selection and justification of regulatory starting materialsMEMBERS
Building best regulatory practices in BrazilMEMBERS
Time is running out for rare pediatric disease designation and priority review voucher programsMEMBERS
The EMA's Veterinary Big Data Stakeholder Forum (Part 2)MEMBERS
New regulatory tools for drug developers: Sharing experienceMEMBERS
Regulatory support for drug development: Maximising options for timely patient access PUBLIC